Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$115.22 CAD
Change Today -2.67 / -2.26%
Volume 289.4K
As of 4:00 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2150 St. Elzéar boulevard West

Laval, QC H7L 4A8


Phone: 514-744-6792

Fax: 514-744-6272

Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical and medical device company. The company develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. Its product portfolio consists of approximately 1,600 products. Segments The company operates through two segments, Developed Markets and Emerging Markets. Developed Markets This segment consists of sales in the U.S. of pharmaceutical products, OTC products, and medical device products, as well as alliance and contract service revenues, in the areas of eye health, dermatology and podiatry, aesthetics, and dentistry; sales in the U.S. of pharmaceutical products indicated for the treatment of neurological and other diseases, as well as alliance revenue from the licensing of various products that the company developed or acquired; and pharmaceutical products, OTC products, and medical device products sold in Canada, Australia, New Zealand, Western Europe, and Japan. Pharmaceutical Products The company’s principal pharmaceutical products are: An Acne franchise, which includes Solodyn, a prescription oral antibiotic approved to treat only the red, pus-filled pimples of moderate to severe acne in patients 12 years of age and older, as well as Ziana, Acanya, Atralin, Retin-A Micro Microsphere 0.08% and ONEXTON Gel, a fixed combination 1.2% clindamycin phosphate and 3.75% benzoyl peroxide medication for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 years of age and older. Wellbutrin XL is an extended-release formulation of bupropion indicated for the treatment of major depressive disorder in adults. Jublia (efinaconazole 10% topical solution), is a topical azole approved for the treatment of onychomycosis of the toenails (toenail fungus). Xenazine is indicated for the treatment of chorea associated with Huntington’s disease. In the U.S., Xenazine is distributed for the company by Lundbeck Inc. under an exclusive marketing, distribution and supply agreement. Targretin Capsules is a retinoid indicated for treatment of Cutaneous T-Cell Lymphoma. Arestin (minocycline hydrochloride) is a subgingival sustained-release antibiotic. Arestin is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. Arestin may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP. Zovirax is a prescription topical antiviral which is active against herpes viruses. Zovirax Cream is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and adolescents (12 years of age and older). Zovirax Ointment is indicated for the management of initial genital herpes. Syprine is a chelating agent indicated for treatment of patients with Wilson's disease (disorder of copper metabolism) who are intolerant of the first-line treatment. Elidel is a topical formulation used to treat mild to moderate atopic dermatitis, a form of eczema. Elidel Cream 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. Prolensa is a non-steroidal anti-inflammatory ophthalmic solution for the treatment of inflammation and pain following cataract surgery. Duromine is a weight loss drug that acts through appetite suppression. Duromine contains the active ingredient, phentermine, in a once daily formulation. Lotemax Gel is a topical corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. This formulation is a technology that allows the drug to adhere to the ocular surface and offer


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:CN C$115.22 CAD -2.67

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,744 JPY -12.00
Eisai Co Ltd ¥8,195 JPY +1.00
Endo International PLC $62.33 USD +1.33
Mylan NV $51.74 USD -0.06
Sun Pharmaceutical Industries Ltd 739.85 INR +3.95
View Industry Companies

Industry Analysis


Industry Average

Valuation VRX Industry Range
Price/Earnings 49.3x
Price/Sales 3.0x
Price/Book 4.7x
Price/Cash Flow 11.5x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VALEANT PHARMACEUTICALS INTE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at